Expert views and insights on blood safety

Merits and pitfalls of automated bacterial culture methods in improving bacterial safety of platelet concentrates

Dr. Sandra Ramirez-Arcos, PhD
Canadian Blood Services
Ottawa, Canada

Transfusion transmitted bacterial infections in patients: why are they often undetected and underreported?

Dr. Richard J. Benjamin, MBChB, PhD, FRCPath
Cerus Corporation,
Concord, California, USA

COVID-19: Lessons learned to safeguard the continuity of blood supply in the Madrid region

Dr. Luisa Maria Barea Garcia, MD
Centro de Transfusión de la Comunidad de Madrid
Madrid, Spain

How pools-of-pools contributes to optimising your PI platelet products

Mr. Jean-Marc Payrat
Cerus Europe B.V.
Amersfoort, the Netherlands

Assessment of plasma preparations in TTP

Prof. Dr. Paul Coppo, MD
CNR-MAT, AP-HP, Hóspital Saint-Antoine
Paris, France

Evolution of the level of blood safety and impact on patient safety: a historic perspective

Dr. Tor Hervig
Haugesund Hospital / University of Bergen
Bergen, Norway

Historical journey to improve screening of platelet components for bacterial contamination

Dr. Sandra Ramirez-Arcos, PhD
Canadian Blood Services and University of Ottawa
Ottawa, Canada

INTERCEPT treated platelets are effective in preventing bleeding

Ass. prof. Dr. Gerda Leitner
Medical University / General hospital Vienna
Vienna, Austria

Overview of the variability in platelet production processes and applied safety measures

Dr. Mohammad R. Abedi, PhD
Örebro University Hospital
Örebro, Sweden

Experiences of standardized volume, pathogen-reduced, pooled plasma for faster availability of components for transfusion

Ms. Marja-Kaisa Auvinen, MD, PhD
Uppsala University Hospital
Uppsala, Sweden

Bacterial safety of platelet components prepared with Amotosalen-UVA photochemical treatment. What can we conclude after 15 years routine experience?

Dr. Laurence M. Corash, M.D.
Cerus Corporation,
Concord, California, USA

How can we guarantee the supply of blood products to patients? Especially with short-life platelet concentrates, even in times of epidemics?

Priv-Doz. Dr. med. Ulrich Kalus
Charité
Berlin, Germany 

Blood safety during the SARS-CoV-2 pandemic and beyond: the impact of pathogen inactivation with the INTERCEPT Blood System

Prof. Salwa Ibrahim Hindawi
King Abdulaziz University
Jeddah, Saudi Arabia

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products Using the INTERCEPT Blood System

Dr. Mohammad R. Abedi, MD, PhD
Örebro University Hospital
Stockholm, Sweden

Production and in vitro quality of pooled whole blood derived PI plasma

Dr. sc. nat. David Goslings, MBA
Blood Transfusion Service Zurich
Zurich, Switzerland

Ordering platelet concentrates: does pathogen inactivation matter to the clinician?

Prof. Dr. Helmut Ostermann
LMU Kliniken, University of Munich
Munich, Germany

Safety surveillance and the introduction of pathogen reduced platelets: the role of national hemovigilance systems in the Cerus post-market clinical follow-up strategy

Dr. John Pitman, PhD
Cerus Corporation
Concord, USA

Clinical performance of INTERCEPT and solvent detergent plasma used with idiopathic thrombotic purpura patients requiring therapeutic plasma exchanges

Dr. Mario Ojeda-Uribe, MD
Groupe Hospitalier Region Mulhouse Sud-Alsace (GHRMSA), Hospital E. Muller
Mulhouse, France

Case study: enabling double dose methodology on Reveos through pathogen inactivation

Ms. Eleonore Tennby
Cerus Europe B.V.
Amersfoort, the Netherlands

Periodontitis increases risk of viable bacteria in freshly drawn blood donations

Dr. Christian Damgaard, DDS, PhD
University of Copenhagen
Copenhagen, Denmark

Stanford Blood Center - the first blood center of its size to implement pathogen reduction for 100% of platelet components

Stanford Blood Center
California, United States

Bacterial contamination rate of platelet components by primary culture and residual risk associated with false negatives: results from two recent
meta-analyses

Dr. Ryan A. Metcalf
University of Utah and ARUP Laboratories
Utah, USA

COVID-19: Perspectives from a virologist on the current pandemic and a look into the future

Prof. Dr. med Ulf Dittmer
University Hospital Essen
Essen, Germany

Bacterial contamination of platelet components, passive vs. active, surveillance, testing and pathogen reduction technologies

Dr. Richard J. Benjamin, MBChB, PhD, FRCPath
Cerus Corporation,
Concord, California, USA

Vector-borne diseases in the Americas and Europe - NAT vs PI

Dr. Susan Stramer, PhD
American Red Cross
Gaithersburg, Maryland, USA

Timing of bacterial inactivation/ testing

Dr. Sandra Ramirez-Arcos, PhD
Canadian Blood Services
Ottawa, Canada

Estimating the risk associated with bacterial contamination of platelets

Dr. Ryan A. Metcalf, MD, CQA
University of Utah Health and ARUP Laboratories
Utah, USA

What does published literature tell us about the clinical efficacy of INTERCEPT treated platelets?

Dr. Joan Cid Vidal
Hospital Clínic
Barcelona, Spain

Cryoprecipitate from pathogen reduced concurrent apheresis plasma: 5-day post-thaw room temperature storage after 2-year frozen shelf-life

Dr. Konrad Rosskopf, MD
Medical University Graz
Graz, Austria

Case study: impact of pathogen inactivation on outdating rates and supply continuity

Ms. Ragna Landrö, BSc
The Blood Bank, The National University Hospital of Iceland, Reykjavík
Reykjavík, Iceland

Transfusing the right product to the right patient

Dr. Fabrice Cognasse, PhD
Auvergne-Rhône-Alpes Regional Blood Center of the French National Blood Establishment,
INSERM 1059 / University of Lyon
Saint-Etienne, France